Table 1.

Clinical correlations for patients with “high” or “low” systemic G-MDSCsa–G-MDSCs levels do not correlate with disease severity.

N = 7N = 18
Age (y)
Performance status (ECOG)
Tumor type
Tumor size (T)
Node status (N)
Adjuvant chemotherapy
Adjuvant endocrine therapy
Breast cancer Subtyped
Metastasis-free interval (y)
Number of metastatic sites
Metastatic site
 Lymph nodes versus not2/57/111.0c
 Lung versus not2/59/90.41c
 Liver versus not1/64/141.0c
 Bone versus not5/214/41.0c
 Visceral versus not4/312/60.67c
 Bone-only versus not1/64/141.0c
Number of CTCs
Peripheral neutrophil count
 Median (range)7.20 (4.00–12.20)4.00 (2.00–10.20)<0.05e,f
  • a The highest level of healthy control G-MDSCs were set as normal range value (10.5% of PBMCs). “Low” G-MDSCs were patients with G-MDSCs below and up to normal range (≤10.5%). “High” G-MDSCs were patients with G-MDSCs levels above the healthy control normal range (>10.5%).

  • b P-value from Pearson’s chi-squared test.

  • c P-value from Fisher’s Exact Test.

  • d Breast cancer subtype was primarily derived from immunohistochemical staining of the metastasis. If no information was available from the metastasis, the subtype was derived by staining of the primary tumor.

  • e P-value from Mann Whitney test.

  • f P < 0.05.